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Abstract
This Strategic Research Agenda identifies current challenges and needs in healthcare, illustrates how biomedical imaging
and derived data can help to address these, and aims to stimulate dedicated research funding efforts.
Medicine is currently moving towards a more tailored, patient-centric approach by providing personalised solutions for
the individual patient. Innovation in biomedical imaging plays a key role in this process as it addresses the current needs
for individualised prevention, treatment, therapy response monitoring, and image-guided surgery.
The use of non-invasive biomarkers facilitates better therapy prediction and monitoring, leading to improved patient
outcomes. Innovative diagnostic imaging technologies provide information about disease characteristics which, coupled
with biological, genetic and -omics data, will contribute to an individualised diagnosis and therapy approach.
In the emerging field of theranostics, imaging tools together with therapeutic agents enable the selection of best
treatments and allow tailored therapeutic interventions.
For prenatal monitoring, the use of innovative imaging technologies can ensure an early detection of malfunctions or
disease.
The application of biomedical imaging for diagnosis and management of lifestyle-induced diseases will help to avoid
disease development through lifestyle changes.
Artificial intelligence and machine learning in imaging will facilitate the improvement of image interpretation and lead to
better disease prediction and therapy planning.
As biomedical imaging technologies and analysis of existing imaging data provide solutions to current challenges and
needs in healthcare, appropriate funding for dedicated research is needed to implement the innovative approaches for
the wellbeing of citizens and patients.
Keywords: Precision medicine, Preventive medicine, Radiology, Diagnostic imaging, Artificial intelligence
Key points
 Innovative biomedical imaging plays a crucial role in
personalised medicine, disease prevention and
therapy monitoring
 Innovative biomedical imaging technologies and
analysis of existing imaging data provide solutions to
current challenges and needs in healthcare
 Appropriate funding for biomedical imaging
research is necessary to implement innovative
approaches addressing citizens’ and patients’ needs
Introduction
Medicine and healthcare in general are experiencing a
major change, moving from reactive to proactive ap-
proaches by providing predictive, preventive and persona-
lised medical solutions for the individual patient.
Particularly, the concept of personalised medicine is pro-
moted by the European Commission as it addresses the
challenges of ineffective treatment and rising healthcare
costs with patient-centred prevention and treatment plans.
Personalised and precision medicine has a huge growth
potential, which provides Europe’s healthcare industry
with the opportunity to further expand its leading pos-
ition, contributing to economic growth and job creation.
Furthermore, Europe needs research, innovation and
applications for the benefit of all. In this context, areas
of research have to be prioritised and research* Correspondence: office@eibir.org
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programmes should focus on high-impact outcomes [1].
In its recently launched work programmes [2], the Euro-
pean Commission has identified a number of healthcare
challenges, e.g. the rising costs of health and care or the
influence of external environmental factors including cli-
mate change on health, that need to be addressed by
Europe’s research community to develop sustainable so-
lutions that will help to overcome those challenges, im-
prove the treatment of patients and lead to better health
and wellbeing for European citizens. The development
and adoption of good-quality and safe e-services can en-
sure that the health systems of Member States become
more efficient and sustainable [3].
However, as stated in the European Council’s conclu-
sions on Health in the Digital Society [4], new opportun-
ities are arising from big data and improved data
analytics capabilities, yet barriers to scaling up the po-
tential in digital health and connected care still need to
be overcome. These include the dominance of data silos,
lack of interoperability and of common standards for
measuring clinical and patient reported outcomes, and
limited access and use of large databases for research
and innovation purposes. Moreover, a lack of funding
and financial incentives exists, which together with mar-
ket fragmentation in the EU and across the spectrum of
services further impedes innovation. Progress in imple-
menting data-driven digital solutions in healthcare re-
quires rigorous validation and testing of new solutions’
clinical effectiveness.
It is the aim of this Strategic Research Agenda for Bio-
medical Imaging to:
 Identify the current challenges and needs in
medicine and healthcare
 Illustrate how biomedical imaging can help address
these challenges
 Stimulate dedicated research funding efforts
Innovative imaging technologies are now allowing re-
searchers to visualise, characterise and measure bio-
logical and molecular phenomena with a hitherto
unattainable precision. For the first time in history, hall-
mark processes of human disease, such as tumourigen-
esis or molecular deposits, can be visualised in real time.
Imaging technologies and computerised radiomics allow
breakthrough discoveries and their application in health-
care and are thus the central tool driving fundamental
research in biomedicine. Technological innovation in
biomedical imaging has been growing in the last decades
and significant advances in the research fields of photon-
ics, physics, chemistry and computing are often quickly
translated into instrumentation or procedures for bio-
medical imaging. This may accelerate medical advances,
but also calls for a need to adapt existing and to
implement new methods and care pathways for better
patient outcomes.
Biomedical imaging is a key component in persona-
lised medicine [5]:
 Personalised prevention will rely on non-invasive or
minimally invasive image-based screening pro-
grammes [5]
 Structural, functional, physiological and molecular
imaging biomarkers affect decisions on the type and
intensity of treatment [5]
 Treatment response assessment with imaging
biomarkers will improve personalised and targeted
treatment [5]
 Imaging-supported non- or minimally invasive
intervention integrates precision diagnosis and
personalised treatment [5] and will contribute to
value-based healthcare [6]
Moreover, biomedical imaging is a forerunner in the
digital transformation of healthcare and a leading discip-
line in the adoption of new innovative solutions like
deep learning and artificial intelligence. Digital health is
essential for ensuring that breakthroughs or innovations
in clinical research are translated into practice
cost-effectively.
The European Institute for Biomedical Imaging Re-
search (EIBIR) is a non-profit organisation with a
network of more than 80 leading European research in-
stitutions and 11 European scientific societies related to
biomedical imaging as shareholders. EIBIR is committed
to coordinate and support the development of biomed-
ical imaging technologies and the dissemination of
knowledge with the ultimate goal of improving the diag-
nosis, treatment and prevention of disease. It supports
research networking activities and plays a key role in
spreading good practice and promoting common initia-
tives and interoperability in the field of biomedical im-
aging research (www.eibir.org).
EIBIR, together with its members and shareholder or-
ganisations, has identified five main challenges which
biomedical imaging can help overcome:
Challenge 1: Meeting the healthcare demands of
Europe’s population through personalised disease
prevention and therapy monitoring facilitated by
medical imaging
Challenge 2: Developing new disease-specific, targeted
and image-guided therapies
Challenge 3: Contributing to a healthy start by
delivering early and improved information on foetal
health and prenatal growth, and preventing the
development of anomalies using advanced imaging
technologies
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Challenge 4: Providing accurate assessments of the
impact of lifestyle and environmental factors on health
supported by medical imaging
Challenge 5: Making Europe the world leader in
machine-learning and artificial intelligence in medical
imaging by exploiting existing data and expertise to im-
plement digital solutions after rigorous clinical
validation.
Challenge 1: Meeting the healthcare demands of
Europe’s population through personalised disease
prevention and therapy monitoring facilitated by
medical imaging
Precision medicine has emerged as a novel healthcare
paradigm during the past decade
The approach for risk prediction and disease prevention
taking into account individual gene variability as well as
environmental and lifestyle factors involves the integra-
tion of information from multiple sources to achieve pa-
tient population stratification and provide more specific
diagnoses, focused treatment and better response assess-
ment. Deep phenotyping in combination with genetic,
biochemical and physiologic biomarkers allows predic-
tion and early assessment of disease. The emerging field
of radiomics links genotypic information to phenotypic
disease manifestations using imaging. Radiomics can
greatly contribute to patient-tailored prevention and
care.
Special attention should be devoted to the develop-
ment of safe and more specific contrast agents, and the
optimisation of acquisition procedures to the character-
istics of the treated patient/pathology enabling precision
radiology.
Clinically oriented research on quality and safety of med-
ical imaging is an essential aspect when advancing precision
radiology. In 2017, five EIBIR shareholder organisations
established the European Alliance for Medical Radiation
Protection Research (EURAMED; www.euramed.eu) and
published a strategic research agenda for radiation protec-
tion in medicine [7], highlighting the research needs in this
field and encouraging sustainable European efforts.
Imaging biomarkers are objectively measurable indica-
tors of biological processes and can be used for the pre-
diction of patient outcome (regardless of therapy) and
response to specific therapies, and for response assess-
ment (monitoring) [8]. The use of imaging biomarkers is
non-invasive—a clear advantage over invasive biopsies
[8]. Another advantage is the assessment and quantifica-
tion of cellular targets for the entire disease burden,
avoiding sampling errors that can occur with heteroge-
neous expressions, as well as the potential for serial
studies of the in vivo effects of a drug or action on the
target [8]. In addition, imaging biomarkers can unravel
specific localised biological pathways and enable
therapeutic targeting of such specific biomolecular
mechanisms [8].
Joint efforts between research institutions and technol-
ogy vendors should lead to the implementation of stan-
dards in image acquisition, production, archiving and
distribution, and ethical use of sensitive data. Such ap-
proaches are a prerequisite for sharing large imaging
data sets across Europe and for the discovery, adoption
and wider use of predictive, prognostic and diagnostic
imaging biomarkers. The European Imaging Biomarker
Alliance (EIBALL) is a joint initiative operating in con-
junction with EIBIR and in collaboration with the Quan-
titative Imaging Biomarkers Alliance (QIBA) and the
European Organisation for Research and Treatment of
Cancer (EORTC) for the development and validation of
new imaging biomarkers.
Examples addressing Challenge 1
Example 1: BRCA1/2 carriers, enhanced imaging-
based monitoring for breast and ovarian cancer
(conventional mammography vs. contrast-enhanced
MRI) Persons carrying mutations in the BRCA1/2 gene
are more likely to develop breast cancer (men and
women), ovarian cancer in women and prostate cancer
in men. Genetic screening of high-risk families allows
the possibility of early detection of disease or indeed
prevention. There is now compelling evidence that MRI
is the most appropriate screening test for breast cancer
in BRCA1/2 carriers. However, screening programmes
are predominantly based on mammography. Future
screening programmes are needed to fully evaluate the
position of MRI in screening women in high-risk cat-
egories. In ovarian cancer (Fig. 1), but also in other can-
cers such as prostate cancer, biomarkers of early disease
in BRCA carriers, such as circulating DNA, are highly
likely to form the basis of future screening in BRCA car-
riers in conjunction with imaging tests, including ultra-
sound (US) and MRI. Imaging has been highly
successful in determining the likelihood of malignancy
in ovarian and prostate masses. Research into translating
this to screening practice is of utmost importance, par-
ticularly in relation to early detection of disease and
treatment stratification by combining circulating and im-
aging biomarkers.
Example 2: Development of arterial spin labelling as
a brain imaging biomarker Arterial spin labelling
(ASL) to measure perfusion has been at the forefront of
physiological imaging without the use of contrast agents
for more than three decades now. In spite of its obvious
advantages in numerous diseases, such as brain tumours
(Fig. 2), dementia or stroke, ASL has remained under-
used. In particular, it has been shown [9] that relative
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tumour blood flow values can be used as an independent
biomarker of glioma grading, while the same biomarker
can accurately distinguish pseudo-progression from true
progression, thereby providing a very important tool for
therapy monitoring [9]. In 2014, a landmark paper estab-
lished a roadmap for all manufacturers and users of this
technology. Based on this, an on-going effort is taking
place to establish a jointly developed EIBALL-QIBA pro-
file detailing guidelines on how to use ASL in clinical
practice. As part of this initiative, a commercial ASL
calibration phantom was recently launched, together
with an online calibration tool. For ASL to finally
Fig. 1 MRI scan of early-stage 1A high-grade serous ovarian cancer. The BRCA1-positive patient was identified through ultrasound screening,
confirmed by MRI. The right ovary contains as cyst with an enhancing nodule (red arrows) demonstrated on the T1 fat-saturated image before
(a) and after (b) contrast administration. The nodule enhances brightly, similar to the adjacent uterine myometrium (white arrow). Detection
of ovarian cancer at this early stage is associated with a significantly improved 5-year survival rate compared with later stages of disease
(courtesy: A. Rockall)
Fig. 2 a–c Example of a 24-year-old female patient, with oligodendroglioma (grade II) in the left frontal lobe. a Cerebral blood flow, imaged by
ASL. Red indicates high blood flow. b T1-Gd and c FLAIR. d–f Example of a 63-year-old female patient with GBM (grade IV) in the right temporal
lobe. d Cerebral blood flow, imaged by ASL. Red indicates high blood flow. e T1 post Gd. f FLAIR. A clear difference in tumour blood flow can be
seen between both patients (courtesy: A. Alsaedi, S. Bisdas)
The European Institute for Biomedical Imaging Research (EIBIR)* Insights into Imaging            (2019) 10:7 Page 4 of 14
become accepted, it will be critical for new studies to
show the repeatability and reproducibility of the assess-
ment of perfusion over time and its increased usefulness
in many clinical neurological affections.
Challenge 2: Developing new disease-specific,
targeted and image-guided therapies
Biomedical imaging is an indispensable tool in
personalised medicine providing information on
localisation, extent, homogeneity and aggressiveness of
disease
Diagnostic imaging procedures are increasingly used to
support individualised and targeted treatment and repre-
sent a mainstay of the progress of personalised medicine
[10]. This may include:
 The use of an imaging technology to monitor a
therapy [10]
 The administration of an imaging agent acting as a
drug surrogate to predict the biodistribution of the
drug [10]
 The co-administration of both a drug and an im-
aging agent to assess in real time the delivery/release
of the therapeutic agent at the pathological site [10]
 The use of an imaging agent to guide surgeons or
interventional radiologists in a (minimally) invasive
procedure [10].
Recent advances in molecular biology proved that drug
response is often a result of different genetic alterations,
but can also arise from micro-environmental and micro-
biome exposure. Altered environmental and genetic fac-
tors can facilitate cancer progression and may also
influence drug effectiveness, if gene mutations are in-
volved in drug metabolism. A better understanding of
the disease biology as well as molecular changes and al-
tered signalling pathways will enable the identification of
patients who may benefit from such treatments. It will
catalyse the development of targeted therapies which
counter the influence of specific molecular drivers con-
tributing to the development and spread of disease, pro-
viding the foundation of precision medicine.
Theranostics is a novel emerging field of treatment in
which diagnostic imaging tools coupled with therapeutic
agents allow precise targeting of a disease at a molecular
level. Theranostics enables tailored interventions, further
personalising healthcare practices to individual patients
for whom a standard therapy is not suitable. However,
more work is needed to identify novel theranostic com-
binations. New diagnostic tracers can be tailored to the
specific needs of stratified patient groups or to rare dis-
eases for which other therapeutic approaches are not yet
available.
For most currently available radionuclide therapies, a
fixed amount of radioactivity is administered, regardless
of patient weight or body surface area. Although these
empirical dosing methods are well-established, safe and
effective, the theranostic approach offers the possibility
for an upfront evaluation of the biodistribution, quantifi-
cation and calculation of the absorbed dose to the target
volumes and critical organs. The development of a per-
sonalised dosimetry-based approach might further im-
prove the outcome and cost benefit of radionuclide
therapies. Although dosimetry is essential for the devel-
opment of radiopharmaceuticals, its potential and clin-
ical use to tailor the administered amount of
radioactivity for each individual patient still needs to be
established and evaluated by randomised controlled tri-
als comparing dosimetry-based versus fixed-activity
approaches.
Examples addressing Challenge 2
Example 3: Theranostics for treatment of metastatic
pancreatic cancer Figure 3 shows an example of thera-
nostics in a patient with a metastatic pancreatic neuro-
endocrine tumour. In the first panel, staging with
68Ga-Dotatate-PET shows a high expression of somato-
statin receptors in the pancreatic tumour, locoregional
lymph nodes and liver metastases. Panel b shows evalu-
ation with SPECT after treatment with 177Lu-Dotatate,
confirming adequate targeting of the tumour sites. The
end-of-treatment 68Ga-Dotatate-PET scan (panel c)
shows a partial remission, particularly of the metastases
in the liver. A recent phase III study shows that treat-
ment with 177Lu-Dotatate results in a significantly higher
response rate and longer progression-free survival than
high-dose octreotide among patients with advanced mid-
gut neuroendocrine tumours. A first interim analysis
shows preliminary evidence of an overall survival benefit
as well [11]. Similar theranostic approaches, such as
68Ga-/177Lu-PSMA in prostate cancer, are currently
under evaluation in clinical trials with promising prelim-
inary results.
Example 4: Cell recruitment to detect and target
cancer for therapy Recent studies have shown that it is
possible to use fibroblast recruitment as a tool for detec-
tion of cancer and targeted therapy [12]. Cells like fibro-
blasts labelled with a fluorescent reporter can be used as
beacons for guidance of biopsy or surgery, as well as for
therapy (Fig. 4). This figure illustrates study results that
show fibroblasts migrate towards cancer cells. Addition-
ally, a therapeutic effect could be seen in this study. De-
livery of the labelled cells stopped the production of
ascitic fluid in the abdomen in an orthotropic model of
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Fig. 3 Theranostics in a patient with a metastatic pancreatic neuroendocrine tumour. a 68Ga-Dotatate-PET scan for staging. b SPECT evaluation
after treatment. c End-of-treatment 68Ga-Dotatate-PET scan (courtesy of J. Kunikowska, Warsaw)
Fig. 4 Fluorescence imaging of a mouse showing fibroblast (red) migration from injection site to location of tumour cells (green). (a) Fibroblast recruitment
to tumour injection site next to intensine. (b) Fibroblast recruitment to tumour patches attached to the peritoneal wall. (c) Fibroblast scattered in the
abdomen of a control mouse without tumour injection. (d) High resolution image of fibroblasts recruited to a tumour. (e) experimental design (green) [12]
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ovarian cancer metastasis and prolonged survival in
mice.
Challenge 3: Contributing to a healthy start by
delivering improved information on foetal health
and prenatal growth and preventing development
of anomalies using advanced imaging technologies
Biomedical imaging plays an important role in assessing
foetal and prenatal health
The placenta is one of the most important organs influ-
encing not just the health of a woman and her foetus
during pregnancy, but also the lifelong health of both.
When it malfunctions, serious problems such as gesta-
tional diabetes, preterm labour and stillbirth can occur.
Placental dysfunction may also lead to health problems
later in life for both mother and child. The early diagno-
sis of foetal malformations and growth anomalies has
the potential to improve foetal prognosis by granting a
treatment plan and by making specialist units and treat-
ments from birth accessible. The diagnostic accuracy of
ultrasound (US), the currently most-used imaging mo-
dality, is however limited.
Novel imaging technologies should be used in clinical
settings. The use of advanced US tools (e.g. elastography),
optoacoustic imaging and quantitative MRI can be essen-
tial for the assessment of placenta function, transport of
nutrients, oxygen, and therapeutics across the placenta
while also detecting aberrations in foetal development
from implantation to birth. Studies should focus on ma-
ternal and foetal risk models including genetic, infectious
and environmental influences for disease prevention.
Enhanced prenatal monitoring has the potential for
early detection and intervention to reduce maternal and
foetal morbidity and mortality. Furthermore, among the
diseases and anomalies encountered in high-risk patients
during pregnancy, e.g. preeclampsia, intrauterine growth
restriction, multi-foetal pregnancies, increased maternal
age and infection (e.g. ZIKA virus) can be diagnosed and
monitored by imaging. In general it can be expected that
further advances in imaging hold a striking promise for
the study of the placenta and the foetus and emerging
technologies can be translated to other organs and open
new research avenues for the benefit of human health.
Examples addressing Challenge 3
Example 5: Foetal and perinatal imaging (US and
MRI) Imaging techniques for prenatal imaging should
be developed to identify in utero foetal growth disturb-
ance, including foetal growth restriction and movement
disorders. Normal foetal movement in the womb is crit-
ical to normal musculoskeletal development, and novel
imaging strategies can play a critical part in diagnosis
and monitoring of these diseases. For example, a
spectrum of techniques including US elastography, mi-
cro CT, quantitative CT and MRI can be used to develop
models of normal foetal movement (Fig. 5), against
which diseases such as developmental hip dysplasia and
foetal akinesia can be assessed. Early diagnosis and rec-
ognition will help reduce the huge societal and financial
impact these diseases have on chronic musculoskeletal
conditions in childhood, in combination with neonatal
screening programmes for, e.g. hip dysplasia. The under-
standing and modelling of relationships between concur-
rent developments such as movement, skeletal system
and the brain are key to the exploitation of perinatal
imaging.
Example 6: BOLD imaging of the placenta While
structural imaging of the foetus and the placenta are
technically established, though not widely available, the
assessment of placental function during pregnancy is
currently a field of research. The gas and nutrient ex-
change between the mother’s and the foetus’ blood cir-
culation via the placenta is essential for the development
of the foetus. Early delivery is recommended for placen-
tal dysfunction but has to be weighed against the risks of
preterm birth. Oxygen exchange is a most relevant func-
tion of the placenta and, due to the high blood volume
methods adopted from functional brain imaging with
MRI, has been proposed to evaluate placental function
(Fig. 6). During an oxygen challenge, the change in
blood oxygen level-dependent (BOLD) signal is mea-
sured. In particular, the time constant of the related oxy-
gen change on the foetal blood circuit side of the
placenta has been shown in early studies to be related to
birth weight or foetal brain and liver volumes. Bio-
markers derived from US measurements of the placenta
and foetus have not correlated similarly well to postnatal
pathologic assessment of the placenta as BOLD MRI
variations. The quantitative determination of placental
oxygenation remains a challenge since the BOLD signal
depends on many parameters that are difficult to assess
non-invasively.
Challenge 4: Providing accurate assessment of
lifestyle and environmental impact factors on
health supported by medical imaging
The impact of lifestyle and environmental factors can be
assessed by medical imaging
According to the WHO [13], 60% of the factors contrib-
uting to individual health and quality of life are corre-
lated with lifestyle. Millions of people follow an
unhealthy lifestyle and encounter illness, disability and
even death because of it. Problems such as metabolic
diseases, joint and skeletal pathologies, cardiovascular
diseases, hypertension and violence can be caused by an
unhealthy lifestyle. The relationship between lifestyle
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and health should be considered as established. Also the
interaction between human health and the environment
has been extensively studied and environmental risks
have been proven to significantly impact human health,
either directly by exposing people to harmful agents, or
indirectly by disrupting life-sustaining ecosystems. Al-
though the exact contribution of environmental factors
to the development of disease and death cannot be pre-
cisely determined, the WHO has estimated that 13 mil-
lion deaths annually are attributable to preventable
environmental causes [14].
The timely use of diagnostic imaging tools as a preventive
measure, followed by lifestyle changes, can prevent disease
development [15]. Due to the increasing prevalence of
obesity and its metabolic manifestations, it is important to
obtain patient-specific quantitative body composition
knowledge to predict and prevent disease [16]. The role of
metabolically active tissues such as brown adipose tissue
needs to be studied with new imaging methods to measure
both mass and metabolic activity, enabling accurate assess-
ments of energy turnover under normal and stimulated
conditions. The identification of management strategies in
Fig. 5 Computational pipeline for developing stress modelling of foetal movements. Foetal joint movements are tracked in utero (a), with finite
element modelling of reaction forces (b) combined with musculoskeletal modelling to predict muscle forces (c) which are then applied to finite
element models of foetal geometries (d). Adapted from [21]
Fig. 6 BOLD imaging analysis of pregnant mice. Representative spatial distribution maps of the oxygen-haemoglobin dissociation inside the
placenta and foetal liver on days 14.5 (a) and 17.5 (b) show distribution and variability [22]
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cardiovascular diseases (CVDs) is of utmost importance, as
the WHO projected that in 10 years from now more than
23 million people will die annually due to CVDs.
The use of biomedical imaging is essential due to its stra-
tegic advantages in diagnostic and therapeutic
decision-making and as it delivers inputs for different stages
of disease management, including prediction, screening,
early diagnosis, staging, prognosis and follow-up. Deep phe-
notyping using imaging in combination with information
acquired from wearable sensors has the significant potential
to monitor subjects and patients during daily activities, pro-
viding information on external factors influencing biological
processes at different levels.
Examples addressing Challenge 4
Example 7: Body fat imaging with quantification The
increase in obesity and metabolic-related diseases is one
the challenges for global healthcare systems. Fat accu-
mulation in organs and muscles is a strong biomarker of
diabetes, the metabolic syndrome and obesity. A com-
prehensive understanding of the volume, distribution
and quality of fat and muscles in the human body is im-
portant for diagnosis and treatment of illness. There is a
need to develop automated segmentation and quantifica-
tion of muscle and fat tissue volumes in the body (Fig. 7)
which can be addressed by MRI. This technique has the
potential to foster links between endocrine and cancer
MRI disciplines and to develop biomarkers of morbidity
in cancer survivors and links between disease entities
such as body fat, diabetes, cancer and sarcopenia. In
addition, the amount of subcutaneous and visceral adi-
pose tissue in the abdomen plays an essential role in the
determination of health risks.
Example 8: MR phenotyping in diabetes and
cardiovascular diseases Imaging plays a highly promis-
ing role in individualised risk assessment, particularly re-
garding population-relevant diseases such as diabetes
mellitus and hypertension. In subjects with established
diabetes or hypertension, there is strong evidence that
the level of detectable subclinical disease burden, such
as an altered myocardial perfusion and/or delayed en-
hancement as assessed by MRI, is highly variable among
patients and has strong prognostic relevance beyond left
and right ventricular function for the occurrence of car-
diovascular events. Thus, a more personalised risk strati-
fication is clearly attainable. Less is known in subjects
with prediabetes or pre-hypertensive stages of the dis-
ease, although there is early evidence that prediabetes is
associated with increased subclinical disease burden,
such as carotid plaque volume and arterial stiffness by
ultrasound, changes of left ventricular function by echo-
cardiography, or findings on native or contrast-enhanced
cardiac MRI (Fig. 8). However, these observations lack a
prospective design or reference group, comprise signifi-
cant selection bias or are not generalisable to a prevent-
ive setting [17]. In order to confirm these early findings
and establish their role in improving clinical care, fur-
ther cross-sectional and longitudinal research in specific
cohorts of patients is strongly warranted [17]. This may
include prospective or nested cohort studies and rando-
mised diagnostic trials [17]. As such, medical imaging
may also add to the understanding of the relationship
between changes in the phenotype and the individual
predisposition for metabolic and cardiovascular diseases
or the interplay with neurovascular diseases from a
pathophysiology point of view. Accurate MRI evaluation
of fat deposits within the liver and pancreas are also crit-
ical hallmarks of the metabolic syndrome.
Challenge 5: Making Europe the world leader in
machine learning and artificial intelligence in
medical imaging by exploiting existing data and
expertise to implement digital solutions after
rigorous clinical validation
Machine learning and artificial intelligence can
substantially improve disease diagnostics and prediction
Medical image data has been accumulating exponentially
since the introduction of digital radiology in the 1990s.
Fig. 7 Men matched for the same BMI and total body fat: Differing ‘adiposity phenotypes’ regarding visceral obesity and subcutaneous obesity
and with different risk profiles (courtesy: A. Persson)
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For this reason, being already completely computerised,
radiology is bound to be the first of all medical special-
ties embracing the use of machine-learning and artificial
intelligence. By 2020, global medical data is expected to
double every 73 days, and on average, each person gen-
erates one petabyte of health-related data across his or
her lifetime [18]. Medical images are a substantial por-
tion of all medical data, estimated to amount to 30% of
all data storage [19]. The amount of data being collected
exceeds our capacity to interpret them, especially when
integrating multiple modalities from vastly different
fields such as radiology, metabolomics and genetics.
Available medical imaging data can be a highly
valuable resource for research on diagnostics, epi-
demiology and drug development. This has led to a
higher interest in the development of data-driven
models based on machine learning (ML) and artificial
intelligence (AI) [18]. Deep learning, based on artifi-
cial neural networks, emerged in recent years as a
powerful tool for ML and promises to reshape the fu-
ture of AI. Increasing computational power allows
ML, and AI in general, to more accurately identify
and generate semantic interpretations from medical
imaging data, supporting diagnoses.
Interpreting images can be highly subjective. ML and
AI can be used to interpret images more consistently, as
well as document metadata and perform data entry. ML
techniques not only have significant potential to improve
diagnoses from medical images, but may also improve
disease prediction, decision-making, treatment planning
and treatment response predictions [20].
Currently, ML and AI in medical imaging are not be-
ing used to their full extent. Beyond supporting diagno-
ses, ML and AI can reduce cost by cutting scan times,
automating post-processing and reducing computation
times for model-based image interpretation. Further-
more, ML and AI can accelerate drug discovery and le-
verage data from multiple sources (including sources
other than medical images) for better care coordination.
Examples addressing Challenge 5
Example 9: Identifying novel phenotypes in lung
diseases A key ability of ML is the exploitation of com-
plex features drawn from multiple modalities and across
the entire patient. Current finding and diagnostic cat-
egories in lung diseases such as fibrosis are lacking in
terms of repeatability and their ability to predict
Fig. 8 Imaging findings in a 61-year-old male indicating extensive subclinical disease burden. a Two-point DIXON T1-weighted sequence for the
assessment of visceral adipose tissue volume from the femoral head to the cardiac apex (arrow) indicating high levels of fat as well as hepatic proton
density fat fraction (asterisk, measured on multi-echo VIBE T1-weighted sequences). b Fluid-attenuated inversion recovery sequences demonstrating
mild white matter lesions (arrowhead). c Atherosclerotic carotid plaque was determined on black-blood T1-weighted fat-suppressed sequences in the
common carotid artery (arrow), the carotid bulb and the proximal internal carotid artery. d Cine-SSFP sequences were evaluated for the calculation of
volume and mass left ventricle (LV). e late gadolinium enhancement was detected on fast-low-single-shot inversion recovery sequence four-chamber
view [23]
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outcome and treatment response. Machine learning can
contribute by identifying those patterns that can be ex-
tracted with high stability and reliability from clinical
imaging data (Fig. 9). It can connect these measurements
with patient information such as smoking history, or
age. Finally, it can mine the resulting descriptions for re-
liable predictors linking current patient status with out-
come and risk that is relevant for individual treatment
decisions to identify predictive markers. Initial results
point to the power of machine learning in this direction,
and we expect dramatic changes in both the characteris-
tics we use for prognosis as well as the way we use them
to treat an individual through the emerging integration
of machine learning in the development of diagnostic
tools, and the day-to-day clinical decision support.
Example 10: Automation of detection and
measurements A wealth of known markers are tedious
and time-consuming to extract from clinical imaging
data. The widening gap between the rapidly increasing
amounts of imaging data acquired during clinical rou-
tine, and the available number of radiologists who can
read images, requires an increase of efficiency, and the
delegation of tasks to machine learning-based algo-
rithms. While the expert focuses on integrating individ-
ual measurements into a comprehensive assessment of
the patient, the machine can reduce the time needed to
screen hundreds of image slices. Examples comprising
vast amounts of imaging data in need of analysis to im-
prove disease diagnosis and prediction include the
detection of nodules in lung imaging, polyps in
CT-colonography, measurement of brain structures in
neurological disease and evaluation of tumour character-
istics for diagnosis and therapy outcome prediction
(Fig. 10).
Overcoming challenges in healthcare through
biomedical imaging research
The EIBIR Strategic Research Agenda for Biomedical
Imaging identifies research areas critical to overcoming
current challenges in healthcare:
 Innovative biomedical imaging plays a key role in
field of personalised medicine as it addresses the
current needs for individualised prevention,
treatment, therapy response monitoring and image-
guided surgery. In the area of disease prevention and
therapy monitoring, the use of non-invasive bio-
markers will lead to improved patient outcome,
therapy prediction and monitoring.
 Innovative diagnostic imaging technologies and
procedures provide information about disease
characteristics and, coupled with biological, genetic
and -omics data, will contribute to an individualised
diagnosis and consecutive targeted therapy
approach. In the emerging field of theranostics,
imaging tools together with therapeutic agents allow
for tailored therapeutic interventions and the
selection of most effective treatments.
Fig. 9 The landscape of lung disease patients based on their CT image data. The distribution illustrates clusters of patients with similar imaging
characteristics confirmed in reported findings. It is a step towards the identification of phenotypes in large-scale medical imaging data. [24]
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 In the area of prenatal monitoring, the use of
advanced imaging technologies with higher
diagnostic accuracy will ensure the early detection of
malfunctions or disease and benefit maternal and
foetal health providing a healthy start in life.
 The use of biomedical imaging for diagnosis and
management of lifestyle-induced diseases followed
by lifestyle changes will help to prevent disease
development.
 The advanced application of Artificial Intelligence
and Machine Learning in imaging data will help to
improve image interpretation and lead to better
disease prediction, decision making and treatment
planning.
In summary, biomedical imaging has the proven po-
tential to address the major challenges in healthcare and
to contribute to the wellbeing of European citizens and
patients.
To realise this potential, investments in biomedical
imaging research are needed to enable the translation
of innovative solutions into clinical practice. More-
over, the appropriate funding will ensure that the
European research community stays in the forefront
of medical science.
Decision makers are invited to consider this docu-
ment in the definition of research topics strategic-
ally recommendable for financing in the next
decades.
Supporting societies
This Strategic Research Agenda for Biomedical Imaging
was developed by EIBIR with the support and input of
its shareholder societies:
European Society of Radiology (ESR)
The ESR is a non-profit organisation representing the gen-
eral interests of radiology in Europe (www.myesr.org).
The aims of ESR are to serve the healthcare needs of the
general public through the support of science, teaching
and research and the quality of service in the field of radi-
ology as well as the promotion and coordination of the
scientific, philanthropic, intellectual and professional ac-
tivities of radiology in all European countries. The ESR
has over 80,800 individual members as well as 109 mem-
ber societies of which 47 are European national radiology
societies, 15 are European radiological subspecialty soci-
eties and European allied sciences and 47 non-European
national radiology societies.
Cardiovascular and Interventional Radiological Society of
Europe (CIRSE)
CIRSE is a non-profit, educational and scientific associ-
ation aiming to improve patient care through the sup-
port of teaching, science, research and clinical practice
in the field of cardiovascular and interventional radi-
ology (IR) (www.cirse.org). CIRSE aims to support edu-
cation and further research in IR, as well as ensuring
excellent patient safety and timely access to IR therapies.
Fig. 10 Radiomics pipeline, with the aim to link imaging features to clinically relevant parameters such as tumour subtype, patient prognosis and
therapy outcome prediction (Courtesy Martijn Starmans and Stefan Klein, Rotterdam)
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CIRSE also actively collaborates with and supports other
scientific, educational, governmental, professional, na-
tional and international organisations considered useful
to the aims of the Society.
European Coordination Committee of the Radiological,
Electromedical and Healthcare IT Industry (COCIR)
COCIR is the European Trade Association representing the
medical imaging, radiotherapy, health ICTand electromedi-
cal industries (www.cocir.org). COCIR is a non-profit asso-
ciation and provides a wide range of services on regulatory,
technical, market intelligence, environmental, standardisa-
tion, international and legal affairs. COCIR promotes har-
monisation of regulatory frameworks, supported by
state-of-the-art international standards. Its industry pro-
vides safe and high-quality products and services, which
contribute to reducing health inequalities and enhance
cost efficiency in healthcare systems.
European Association of Nuclear Medicine (EANM)
EANM is the umbrella organisation representing nuclear
medicine in Europe and represents 40 National Member
Societies, approximately 3200 individual members and
around 30,000 professionals working in nuclear medi-
cine in Europe (www.eanm.org). EANM aims to advance
science and education in nuclear medicine for the bene-
fit of public health, relating to the diagnosis, treatment,
research and prevention of diseases through the use of
unsealed radioactive substances and the properties of
stable nuclides in medicine, throughout Europe.
European Federation of Organisations for Medical Physics
(EFOMP)
The EFOMP serves as an umbrella organisation repre-
senting 34 national member and affiliated organisations
of more than 8100 physicists and engineers working in
the field of medical physics in Europe (www.efomp.org).
EFOMP aims to harmonise and advance medical physics
in both its professional clinical and scientific expression
throughout Europe by bringing about and maintaining
systematic exchange of professional and scientific infor-
mation, through the formulation of common policies,
and by promoting education and training programmes.
European Federation of Radiographer Societies (EFRS)
The EFRS is a non-profit umbrella organisation repre-
senting 39 professional societies and 60 educational
institutions representing over 100,000 radiographers
across Europe (www.efrs.eu). The aims of the EFRS
are to represent, promote and develop the profession
of radiography in Europe, across medical imaging, nu-
clear medicine and radiotherapy areas of radiography
practice.
European Organisation for Research and Treatment of
Cancer (EORTC)
EORTC is an independent, non-profit cancer research
organisation, with the mission to coordinate and con-
duct international translational and clinical research to
improve the standard of cancer treatment for patients
(www.eortc.org). EORTC aims ultimately to increase
people’s survival and quality of life by testing new thera-
peutic strategies based on existing drugs, surgery and
radiotherapy and also helps develop new drugs and ap-
proaches in partnership with the pharmaceutical indus-
try and in patients’ best interests.
European Society for Magnetic Resonance in Medicine
and Biology (ESMRMB)
ESMRMB is a non-profit society, which aims to support
educational activities and research in the widest sense in the
field defined by the society’s name (www.esmrmb.org). The
ESMRMB is open to physicians, engineers, scientists and
other individuals who are interested in the developments or
the introduction of magnetic resonance techniques in the
fields of medicine and biology.
European Society of Paediatric Radiology (ESPR)
ESPR aims to organise and bring together physicians in-
volved in the field of paediatric imaging, to contribute to
the progress of paediatric imaging particularly within
but also outside Europe, to encourage training and edu-
cation with other branches of medical imaging and
paediatrics in clinical, scientific, education and research
fields (www.espr.org).
European Society for Radiotherapy and Oncology (ESTRO)
ESTRO is a non-profit scientific organisation representing
radiation oncologists, medical physicists, radiobiologists
and radiation therapists with over 5000 members both
within and outside Europe (www.estro.org). ESTRO aims
to foster the role of radiation oncology in order to im-
prove patient care in the multimodality treatment of can-
cer by promoting innovation, research and dissemination
of science through its congresses, special meetings, educa-
tional courses and publications.
European Society of Medical Imaging Informatics
(EuSOMII)
EuSoMII is a professional healthcare organisation that pro-
vides its members and the radiological community with
up-to-date information on the latest innovations and
achievements in medical imaging informatics by supporting
education, research and events related to the top-tier soft-
ware in radiology (www.eusomii.pro).
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